What is it about?
Deficiency of magnesium results in diseases that cause incalculable suffering and costs worldwide. In this study, we examined the effect magnesium supplementation on metabolic profiles in hypomagnesemic obese and pre-diabetic patients in stage 2 and 3 of chronic kidney disease.
Featured Image
Photo by Robina Weermeijer on Unsplash
Why is it important?
An early optimisation of magnesium may delay or decrease the incidence of diabetes in pre-diabetic chronic kidney disease patients and return insulin resistance to normal in study patients. In this study, we showed that a 3-month oral administration of magnesium oxide improved the metabolic profile – and especially insulin sensitivity – in pre-diabetic and obese patients with stage 2 and 3 chronic kidney disease.
Perspectives
The diagnosis of obesity, pre-DM or chronic kidney disease is not difficult, and magnesium measurement is an easily available and inexpensive marker. Therefore, checking magnesium levels in metabolically disturbed pre-diabetic and obese patients with stage 2-3 chronic kidney disease is recommended. If hypomagnesemia is detected, magnesium supplementation can be a useful guide for improving the metabolic status in these patients.
MD Omer Toprak
Balikesir University School of Medicine, Division of Nephrology
Read the Original
This page is a summary of: Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study, Kidney and Blood Pressure Research, January 2017, Karger Publishers,
DOI: 10.1159/000468530.
You can read the full text:
Contributors
The following have contributed to this page
